Project Grant R01AI180125
Award Date
7/23/24
Completion Date
6/30/29
Dollars Obligated
$686K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $558,501 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Albert Einstein College of Medicine to support a highly collaborative research project focused on reverse-engineering the functions of the Crimean-Congo Hemorrhagic Fever Virus (CCHFV) glycoprotein complex. The overarching goal is to address critical gaps in understanding the structure, assembly, and roles of CCHFV glycoproteins in viral...
This federal Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), totals $38,056,004 and is focused on developing strategies effective against pathogenic picornaviruses and bunyaviruses. The award supports five research projects that aim to advance vaccine and antibody-based countermeasures for viruses such as enteroviruses, hantaviruses, and arenaviruses. Key products and...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $232,415 Project Grant to the University of California, Davis. This grant supports research aimed at preventing primary cytomegalovirus (CMV) infection through the use of a potent CMV-encoded IL-10 neutralizing monoclonal antibody. The key objectives of this project are to: 1) Characterize and purify highly potent viral IL-10 neutralizing...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is focused on the development of broadly neutralizing nanobodies for advancing AIDS therapy. The $1,501,625 award aims to identify and engineer nanobodies capable of recognizing diverse regions of the HIV envelope protein, with the primary goal of improving treatment effectiveness and simplifying therapeutic protocols. Key objectives include: 1)...
This federal Project Grant award, with ID R01AI185102, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $809,614 award is funding a 5-year research project to develop broadly neutralizing human monoclonal antibodies (BNAbs) against henipaviruses, a class of highly pathogenic viruses that cause severe respiratory and neurological diseases in humans and animals. The primary objectives are...
This federal Project Grant award of $107,948 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research aimed at engineering B cells to secrete broadly neutralizing antibodies that could help control HIV in people living with the virus. The key objectives are to: 1) design synthetic protein signaling molecules to enhance B cell function, 2) test the ability of these...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to improve the understanding of how antibodies can control viral infections through Fc-dependent mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytolysis (CDC). The $318,085 award, effective from December 23, 2024 to...
The federal Project Grant award in the amount of $859,597.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel HIV vaccine candidate. The key objective is to elicit broadly neutralizing antibody responses against the HIV-1 fusion peptide epitope using immunogens based on AB toxin B subunits, such as cholera toxin B (CTB). The award supports a multi-year research...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), is supporting a study of acute HIV infection to investigate strategies for HIV eradication. The $794,045 award to The Regents of the University of California, San Francisco (UCSF) aims to identify host cellular mechanisms that drive HIV reservoir decay and sustained viral control, with the goal of informing...
This $782,871 federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate mechanisms by which arthritogenic alphaviruses, such as chikungunya and Ross River viruses, evade CD8+ T cell-mediated immunity. The primary goals are to: 1) determine how type I interferon restricts alphavirus infection of antigen-presenting cells, impairing the...